GlobeNewswire

Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
17/03/2026
- First ZEVASKYN ® commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 – - $191.4M in cash, cash equivalents and short-term investments as of December 31, 2025 [...]
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
17/03/2026
Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026 Obtained alignment with FDA and global regulators for planned Phase 3 trial design in patients with DLB [...]
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs
17/03/2026
Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potential NEW YORK, March 17, 2026 (GLOBE [...]
Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms
17/03/2026
WINNIPEG, Manitoba, March 17, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) announces that Frontiers in Antibiotics has published a peer-reviewed article authored by researchers from [...]
Transpire Bio Strengthens its Leadership Team with Appointment of Ewan Livesey as Head of Business Development
17/03/2026
SUNRISE, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., a U.S. based, clinical-stage, revenue-generating biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic [...]
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
17/03/2026
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global development and [...]
Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026
17/03/2026
BURLINGTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 [...]
Endogenex Announces Publication of REGENT-1 Clinical Study Results in Diabetes, Obesity and Metabolism
17/03/2026
Peer-Reviewed Data Show Durable HbA1c Reduction, Significant Weight Loss, and a Favorable Safety Profile Through 48 Weeks Following a Single Endoscopic Procedure for Type 2 Diabetes MINNEAPOLIS, March 17, 2026 (GLOBE [...]
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
17/03/2026
Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated in H2 2026 Newly [...]
Picard Medical / SynCardia Announce Successful Four-Year Bridge to Transplant with SynCardia Total Artificial Heart Support
17/03/2026
29-year-old patient supported for more than 1,600 days on the SynCardia Total Artificial Heart before receiving a donor heart transplant TUCSON, Ariz., March 17, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE [...]
Vireo Growth Inc. Announces Fourth Quarter 2025 Results
17/03/2026
Q4 GAAP revenue of $104.5 million increased 317.7% year-over-year, driven by recently closed M&A transactions On a pro forma basis, Q4 same store sales increased 22% year-over-year and wholesale revenue increased 55 [...]
Asimov Announces Cell Line Development Partnership with Score Pharma to Advance Biosuperior Antibody Therapeutics
17/03/2026
Score will leverage Asimov’s CHO Edge system to accelerate the development of enhanced cancer immunotherapies with improved ADCC activity BOSTON, March 17, 2026 (GLOBE NEWSWIRE) -- Asimov, the synthetic biology company [...]
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
17/03/2026
For the first time, Eupraxia is reporting 24-week data on symptom response from the highest dose cohort in the open label, Phase 1b/2a portion of the RESOLVE trial. The data is important because it is from one of the [...]
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
17/03/2026
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (Nasdaq: GYRE), a San Diego-based innovative commercial stage biopharmaceutical company with operations in the United [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application
17/03/2026
Determination of bioequivalence to the Reference Listed Drug is essential for approval of an Abbreviated New Drug Application (ANDA). FDA has advised NRx in written correspondence that it has not identified any [...]
IgNS and ACHC Launch New Distinction to Elevate Standards in Immunoglobulin Therapy
17/03/2026
CARY, N.C., March 17, 2026 (GLOBE NEWSWIRE) -- The Accreditation Commission for Health Care (ACHC) has partnered with the Immunoglobulin National Society (IgNS) to launch the Distinction in Immunoglobulin Therapy. This [...]
Avance Clinical Appoints Liahna Toy to Lead Global Early Phase Center of Excellence, Advancing Accelerated Early Phase Delivery for Biotechs
17/03/2026
ADELAIDE, Australia, March 17, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, a global full-service CRO headquartered in Australia dedicated to servicing biotech, announces the appointment of Liahna Toy as Senior Vice [...]
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation
17/03/2026
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, [...]
Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet
17/03/2026
BROOMFIELD, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum